BioCentury | Apr 9, 2021
Product Development

Ventus raises RA-led $100M series B that will enable human trials, open path to IPO

Less than a year after emerging from stealth with $60 million, Ventus has added $100 million to its coffers in a series B round that could drive two programs into the clinic and enable the...
BioCentury | Mar 19, 2021
Product Development

Self-amplifying may be the next frontier in RNA therapies

With the success of mRNA vaccines for COVID-19 solidifying the technology as a vaccine modality that’s here to stay, the conversation has turned to where mRNA will make its mark next and what’s...
BioCentury | Mar 11, 2021
Emerging Company Profile

Ventyx emerges with $114M to bring asset-centric immunology plays under one umbrella

Ventyx is the second start-up in the past month to bundle asset-centric companies under one umbrella with an eye towards advancing each program faster than the originator companies could have had they...
BioCentury | Feb 20, 2021
Product Development

BMS turns to mechanistic diversity in early oncology pipeline

As BMS builds out its early pipeline to find its next big act in cancer and head off revenue losses from upcoming patent cliffs, it’s taking a broad sweep across oncology’s hottest target spaces...
BioCentury | Jan 12, 2021
Product Development

Mesoblast to seek advancement of heart failure cell therapy on 60% composite CV outcomes reduction

A composite analysis showing reductions in cardiac death, stroke and heart attack in Mesoblast’s Phase III heart failure trial appears to have allayed investor concerns following the December disclosure...
BioCentury | Dec 18, 2020
Management Tracks

Rim named CEO of Samsung Biologics as Sarepta unveils promotions; plus Coughlin, Iovance, SpringWorks and NodThera

Samsung Biologics promoted EVP John Rim to president and CEO. Before joining the South Korean company in 2018, Rim worked for Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit for 14 years in senior global...
BioCentury | Dec 12, 2020

Forbion to focus record €460M fund on early-stage opportunities

Increased deal flow across the board has led Forbion to split its funds between early and late-stage opportunities, with its latest €460 million ($557.7 million) fund, which closed this week, focused...
BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

A VC syndicate that backed IFM and serial dealmaker Gary Glick has launched precision oncology start-up Scorpion, where Glick will be president and CEO, with $108 million in series A funding. Scorpion...
BioCentury | Oct 17, 2020

Novartis Venture Fund’s move to earlier, riskier bets starting to pay off

Over the last three and a half years, Novartis Venture Fund has remade its team and narrowed its remit to early-stage opportunities in therapeutics. The fund’s 2020 exits suggest the strategic shift may...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
Items per page:
1 - 10 of 100